Overview

Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II study of the combination of etanercept and rituximab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This combination is proposed to improve the efficacy and diminish the toxicity of this the
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
John Byrd
Ohio State University Comprehensive Cancer Center
Treatments:
Etanercept
Rituximab